Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:GANX NASDAQ:HRTX NASDAQ:LONA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$2.01$4.80$1.95▼$19.35$17.31M1.24218,245 shs191,888 shsGANXGain Therapeutics$1.88$1.84$1.41▼$4.34$80.19M0.16664,211 shs499,893 shsHRTXHeron Therapeutics$0.42$0.83$0.38▼$2.30$79.02M1.584.46 million shs5.46 million shsLONAAthira Pharma$8.18$9.24$2.85▼$14.21$76.84M1.9720,936 shs8,646 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics+1.01%-22.39%-57.59%-62.29%-83.32%GANXGain Therapeutics+5.62%+11.24%+18.99%-3.59%+5.03%HRTXHeron Therapeutics+7.80%+3.60%-50.77%-46.38%-79.13%LONAAthira Pharma-0.61%-3.65%-18.93%-17.54%+817,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$2.01$4.80$1.95▼$19.35$17.31M1.24218,245 shs191,888 shsGANXGain Therapeutics$1.88$1.84$1.41▼$4.34$80.19M0.16664,211 shs499,893 shsHRTXHeron Therapeutics$0.42$0.83$0.38▼$2.30$79.02M1.584.46 million shs5.46 million shsLONAAthira Pharma$8.18$9.24$2.85▼$14.21$76.84M1.9720,936 shs8,646 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics+1.01%-22.39%-57.59%-62.29%-83.32%GANXGain Therapeutics+5.62%+11.24%+18.99%-3.59%+5.03%HRTXHeron Therapeutics+7.80%+3.60%-50.77%-46.38%-79.13%LONAAthira Pharma-0.61%-3.65%-18.93%-17.54%+817,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 2.00Hold$24.501,118.91% UpsideGANXGain Therapeutics 2.67Moderate Buy$8.50352.13% UpsideHRTXHeron Therapeutics 2.00Hold$2.50498.80% UpsideLONAAthira Pharma 2.40Hold$15.0083.37% UpsideCurrent Analyst Ratings BreakdownLatest ATOS, GANX, LONA, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.006/2/2026HRTXHeron Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/27/2026GANXGain Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/27/2026LONAAthira Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/22/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/12/2026GANXGain Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$4.57 per shareN/AGANXGain Therapeutics$50K1,603.64N/AN/A$0.48 per share3.92HRTXHeron Therapeutics$154.90M0.51N/AN/A$0.07 per share5.96LONAAthira PharmaN/AN/AN/AN/A$2.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$34.77M-$3.21N/AN/AN/AN/A-84.91%-72.36%8/11/2026 (Estimated)GANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/11/2026 (Estimated)LONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/ALatest ATOS, GANX, LONA, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million5/8/2026Q1 2026ATOSAtossa Genetics-$0.99-$1.11-$0.12-$1.11N/AN/A5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A3/26/2026Q4 2025GANXGain Therapeutics-$0.14-$0.11+$0.03-$0.11$0.03 millionN/A3/26/2026Q4 2025LONAAthira PharmaN/A-$18.90N/A-$18.90N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A4.924.92GANXGain Therapeutics0.024.694.69HRTXHeron Therapeutics17.512.531.51LONAAthira PharmaN/A10.3810.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%GANXGain Therapeutics11.97%HRTXHeron Therapeutics80.01%LONAAthira Pharma57.12%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics9.80%GANXGain Therapeutics4.15%HRTXHeron Therapeutics6.10%LONAAthira Pharma25.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics88.61 million7.77 millionOptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableHRTXHeron Therapeutics300189.28 million177.73 millionOptionableLONAAthira Pharma409.39 million6.98 millionN/AATOS, GANX, LONA, and HRTX HeadlinesRecent News About These CompaniesAthira Pharma (NASDAQ:LONA) Shares Up 4.4% - Here's WhyJune 18 at 2:29 AM | americanbankingnews.comLeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development SummitJune 4, 2026 | globenewswire.comLeonaBio to Participate in Upcoming Medical and Industry Meetings in JuneMay 27, 2026 | globenewswire.comLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comLeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.May 7, 2026 | globenewswire.comLeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene TranscriptApril 29, 2026 | seekingalpha.comLeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast CancerApril 23, 2026 | globenewswire.comLeonaBio Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 26, 2026 | globenewswire.comAthira Pharma (NASDAQ:LONA) CEO Sells 5,156 SharesMarch 6, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 2026Investors Abandoned These 3 AI Stocks Too Early, Says Jeff ClarkBy Bridget Bennett | May 21, 2026ATOS, GANX, LONA, and HRTX Company DescriptionsAtossa Genetics NASDAQ:ATOS$2.01 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.00 -0.01 (-0.30%) As of 06/18/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Gain Therapeutics NASDAQ:GANX$1.88 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.87 -0.01 (-0.37%) As of 06/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Heron Therapeutics NASDAQ:HRTX$0.42 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.42 +0.00 (+0.12%) As of 06/18/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Athira Pharma NASDAQ:LONA$8.18 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$8.44 +0.26 (+3.12%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
